3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
pembrolizumab
58
Nivolumab
37
aldesleukin
16
Cyclophosphamide
15
atezolizumab
12
Specimen Handling
11
Radiosurgery
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
Ipilimumab
9
Interleukin-2
9
fludarabine
8
fludarabine phosphate
7
Docetaxel
7
Carboplatin
7
avelumab
6
Radiotherapy
6
durvalumab
5
Peripheral Blood Stem Cell Transplantation
5
Immune Checkpoint Inhibitors
5
Cisplatin
5
Bevacizumab
5
tislelizumab
4
temsirolimus
4
spartalizumab
4
Sirolimus
4
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Cryosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Patient Reported Outcome Measures
×
Dermatologic
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled